NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
13 Januar 2010 - 7:59PM
PR Newswire (US)
DURHAM, N.C., Jan. 13 /PRNewswire-FirstCall/ -- Oxygen
Biotherapeutics, Inc. (OTC:OXBT) (BULLETIN BOARD: OXBT) announced
today that the company's common stock will begin trading on the
NASDAQ Capital Market with the opening of trading on Friday,
January 15, 2010. The shares will continue to trade under the
symbol OXBT. In addition, company chairman and CEO Chris Stern will
be in New York to ring the opening bell at the NASDAQ one week
later on Friday, January 22. About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing
innovative pharmaceuticals and medical devices in the field of
oxygen therapeutics and Defense Medicine(TM). The company has
developed a perfluorocarbon (PFC) therapeutic oxygen carrier and
liquid ventilation product (Oxycyte(TM)) and has out-licensed an
implantable glucose sensor. These products are based upon core
technologies that include biomedical applications for PFCs as well
as medical and industrial applications for biosensors. Each of the
product candidates is designed with advantages over currently
marketed products in major markets including traumatic brain
injury, sickle cell crisis, trauma, wound care, decompression
sickness, acute respiratory distress syndrome, stroke, myocardial
infarction, surgery, diabetes wounds and ulcers, and cosmetic
applications which are being marketed under the Dermacyte name.
More information is available at http://www.oxybiomed.com/.
DATASOURCE: Oxygen Biotherapeutics, Inc. CONTACT: Abe Wischnia of
Abe Wischnia & Associates, +1-619-795-2345, for Oxygen
Biotherapeutics, Inc. Web Site: http://www.oxybiomed.com/
Copyright